Develops an investigational antibody treatment targeting amyloid-beta oligomers for people with early Alzheimer’s disease, and is also developing brain-penetrating antibody therapies for Alzheimer’s disease.
10-K for FY2025, filed Mar 26, 2026
10-Q for Q3 FY2026, filed Oct 26, 2026
−$25.4MView ↗
8-K, filed Jun 16, 2026
One of the two EBD development candidates selected by the Company for further development is a bispecific antibody derived from sabirnetug…View ↗
An added brain-delivery program
The older report focuses on its amyloid-beta oligomer-targeting antibody; the latest report also describes a brain-penetrating therapy developed with JCR.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 26, 2026We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key…View ↗
In addition, we are investigating a blood-brain barrier-penetrating, Aß oligomer-targeted Enhanced Brain Delivery (EBD™) therapy for the…View ↗
Subcutaneous development
The older report describes intravenous development of its antibody candidate; the latest report also describes a subcutaneous formulation of sabirnetug.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 26, 2026Our product candidate, ACU193, is a recombinant humanized, affinity-matured, immunoglobulin G2, or IgG2, subclass monoclonal antibody…View ↗
We are currently developing sabirnetug for IV administration Q4W for the treatment of early AD, and we have begun developing sabirnetug for…View ↗
Competes with AbbVie, Alector, Alnylam Pharmaceuticals, AltPep, Alzheon, Alzinova, BioArctic, Biogen, Bristol-Myers Squibb, Cognition Therapeutics, Denali, Eisai, Eli Lilly, Grifols, Korsana Biosciences, Neurimmune, Priavoid, ProMIS Neurosciences, Prothena Biosciences, and Roche
10-K for FY2025, filed Mar 26, 2026Other companies known to be developing therapies with Aß-, AßO- and amyloid plaque-related targets include AbbVie Inc., or Abbvie, Alector…View ↗
Loading...